What does it mean if a drug has 17 generic manufacturers?

Generic manufacturer count is the single best leading indicator of plan-side pricing leverage on a molecule. The more manufacturers shipping, the deeper the competition for wholesale orders, and the lower the NADAC acquisition cost floor.

Empirical pattern observed in CMS NADAC data:
- 1-3 manufacturers: limited price competition, NADAC remains near brand
- 5-10 manufacturers: competitive pricing emerges, NADAC drops 60-80% from brand
- 15+ manufacturers: deep competition, NADAC stabilizes at 5-10% of original brand price
- 25+ manufacturers: commodity pricing, NADAC measured in pennies per unit

Rivaroxaban with 17 manufacturers has a NADAC floor of $0.98/unit on 2.5 MG generic tablets. Apixaban with only 2 manufacturers has a NADAC floor of $5.51/unit. Same drug class. The structural reason for the 5x price difference is generic depth, not anything intrinsic to the molecules.

Plans should treat high manufacturer count as a green flag for tier-move and pass-through pricing negotiations: there is no rebate-side reason for the PBM to resist, and supply security is high.